PFIZER'S CENTERS FOR THERAPEUTIC INNOVATION (CTI)

REQUESTS PROPOSALS FOR THERAPEUTIC TARGETS

Deadline (Cycle 1): April 23rd, 2018

PFIZER RESOURCES | US GOVERNMENT AGENCIES | FOUNDATIONS | ACADEMIC MEDICAL CENTERS

Pfizer's Centers for Therapeutic Innovation (CTI) is a unique collaboration approach that partners with leading academic medical centers to rapidly translate novel target opportunities into potential new medicines.

CTI Collaborations Include

- Funding of project-related research
- Potential for financial awards in the form of milestone and royalty payments for successful programs
- Dedicated hands-on partnering with Pfizer drug-development experts
- Support by Pfizer's science and technology teams
- Flexible publishing terms
- Potential for involvement with CTI's Foundation alliance partners

Modalities Considered

- **Large Molecules**: antibodies, proteins, fusion proteins, antibody conjugates
- **Small Molecules***: target classes include kinases, deubiquitinating enzymes, GPCRs, ion channels, solute transporters, and epigenetic targets

**(if applicable to institution's Participation Agreement)*

Pre-Proposal Submission Process

Submission entails a non-confidential 2-3 page overview (template provided) of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the proposal should suggest how the therapeutic

All researchers and clinicians whose work meets these criteria are invited to apply. **Please discuss your ideas with your contacts below. Non-confidential pre-proposals are to be submitted to your Technology Transfer Office by April 23, 2018.**

Therapeutic Areas of Interest for Spring 2018

- **Oncology**: Targets/Pathways that:
  - Enhance anti-tumor immune responses alone or in combination with Standard of Care
  - Enhance immune surveillance (e.g., tumor neoAg recognition)
  - Target unique aspects of tumor or TME metabolic activity
  - Exploit vulnerabilities in tumor heterogeneity, senescence, plasticity
  - Promote or enable tumor selective/specific drug delivery or targeting
- **Inflammation and Immunology**: Targets/Pathways that:
  - Regulate tissue-specific immune cell activation or function
  - Exploit immune cell or lineage specific metabolic pathways
  - Modulate inflammation and/or tissue remodelling and repair in the context of liver fibrosis (NAFLD/NASH)
  - Promote gut epithelial barrier health and integrity
  - Regulate antigen-specific tolerance induction and/or modulate T regulatory cells
- **Cardiovascular and Metabolic Diseases**: Targets/Pathways that:
  - Reverse hepatic steatosis associated with NAFLD/NASH
  - Inhibit lipolysis to treat NAFLD/NASH
  - Reverse cachexia experienced by patients with cancer or chronic diseases such as heart failure, chronic kidney disease and COPD
  - Reverse muscle insulin resistance in patients with T2DM
  - Improve heart failure by specifically correcting defects in cardiac metabolism
- **Rare Diseases**: Targets/Pathways that:
  - Represent novel targets for non-malignant hematologic indications (including sickle cell disease and complement mediated diseases)
  - Address skeletal and cardiac muscle diseases (including Duchenne or Becker muscular dystrophies)
  - Treat repeat expansion diseases including Huntington's disease, ALS/FTD and myotonic dystrophy

For More Information

Please contact Nader Halim at Nader.Halim@pfizer.com and Columbia Tech Ventures at techventures@columbia.edu

CTI
Centers for Therapeutic Innovation
www.PfizerCTI.com

COLLABORATIVE | ENTREPRENEURIAL | RESULTS-DRIVEN